Circulation:糖尿病心血管疾病患者的危险因素和预后的关系

2017-06-19 MedSci MedSci原创

改变一些危险因素可以显着改善伴有糖尿病的心血管患者的预后。但是,将这些危险因素改变到什么程度才能最大化改善预后仍没有大型的临床试验数据支持。

改变一些危险因素可以显著改善伴有糖尿病的心血管患者的预后。但是,将这些危险因素改变到什么程度才能最大化改善预后仍没有大型的临床试验数据支持。

本研究通过对来自38个国家的13616例患有糖尿病和心血管疾病的患者在以下5个指标进行分析评估:阿司匹林的使用、脂质的控制(低密度脂蛋白胆固醇<70mg/dl或接受他订类药物治疗)、血压控制(收缩压<140mmHg,舒张压<90mmHg)、血管紧张素转换酶抑制剂或血管紧张素受体阻断剂的使用和无烟状态。利用Logistic回归评估个体与区域因素和二级预防成果的关系。利用Cox比例风险回归分析评估基线的二级预防成果与心源性死亡、心梗和卒中的关系。

研究结果显示,有71.8%的患者达到了其中的4个指标,而29.9%的患者达到了全部的5个指标。其中以北美的患者居多(41.2%),西欧、东欧和拉丁美洲约占25%。在个体因素中,血压控制(57.9%)达标率最低,而无烟状态(89%)的达标率最高。通过超过平均3年的随访时间,发现高的二级预防成果分数与良好的预后结局是相关的(HR:0.6[95% Cl:0.47-0.77]相对于这些达到5个指标和≤2个的患者来说)。

本次大型临床研究结果证实,通过改变危险因素是可以显著改善伴有糖尿病心血管患者预后的。

原始出处:

Neha J. P et al.Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial.Circluation.2017 June.

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798989, encodeId=eb5f1e9898930, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 12 22:51:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804278, encodeId=86dd18042e8ef, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Jul 15 17:51:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213631, encodeId=4164213631f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Jun 21 22:24:02 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498209, encodeId=042314982090c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 20 23:51:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212684, encodeId=6716212684db, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=79351625688, createdName=1dd7a091m35(暂无匿称), createdTime=Mon Jun 19 09:49:27 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798989, encodeId=eb5f1e9898930, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 12 22:51:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804278, encodeId=86dd18042e8ef, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Jul 15 17:51:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213631, encodeId=4164213631f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Jun 21 22:24:02 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498209, encodeId=042314982090c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 20 23:51:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212684, encodeId=6716212684db, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=79351625688, createdName=1dd7a091m35(暂无匿称), createdTime=Mon Jun 19 09:49:27 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1798989, encodeId=eb5f1e9898930, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 12 22:51:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804278, encodeId=86dd18042e8ef, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Jul 15 17:51:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213631, encodeId=4164213631f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Jun 21 22:24:02 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498209, encodeId=042314982090c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 20 23:51:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212684, encodeId=6716212684db, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=79351625688, createdName=1dd7a091m35(暂无匿称), createdTime=Mon Jun 19 09:49:27 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-21 明崖

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1798989, encodeId=eb5f1e9898930, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 12 22:51:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804278, encodeId=86dd18042e8ef, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Jul 15 17:51:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213631, encodeId=4164213631f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Jun 21 22:24:02 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498209, encodeId=042314982090c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 20 23:51:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212684, encodeId=6716212684db, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=79351625688, createdName=1dd7a091m35(暂无匿称), createdTime=Mon Jun 19 09:49:27 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1798989, encodeId=eb5f1e9898930, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Nov 12 22:51:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804278, encodeId=86dd18042e8ef, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Jul 15 17:51:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213631, encodeId=4164213631f5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Jun 21 22:24:02 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498209, encodeId=042314982090c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 20 23:51:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212684, encodeId=6716212684db, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=79351625688, createdName=1dd7a091m35(暂无匿称), createdTime=Mon Jun 19 09:49:27 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-19 1dd7a091m35(暂无匿称)

    学习了。。。。。

    0

相关资讯

Heart:房颤的临床表现和预后有性别差异?

近日,在国际心血管权威杂志《Heart》上发表了一篇大型临床研究,旨在评估房颤患者在临床表现、管理和预后方面的性别差异。

JAHA:利伐沙班在植入有CIED的房颤患者中的安全性和有效性研究

房颤的发生率和死亡率均较高。系统地接受抗凝治疗可以有效地防止房颤患者中风的发生,尽管在植入有心脏可植入电子设备(CIED)的患者中接受华法林治疗得到了很好的研究,但是在这种情况下,使用口服因子Xa抑制剂的临床数据却十分有限。

SCI REP:心房颤动作为心肌梗死和心血管死亡的预后指标!

这些结果表明心房颤动是心肌梗死、心血管死亡和心血管事件的独立危险因素。

Heart:BP-BES植入术后远期(8-10年)的随访结果出炉!

目前,对于生物可降解聚合物包被的生物膜洗脱支架(BP-BES)植入后的有效性和安全性随访数据仅限于5年。本研究旨在评估BP-BES植入后远期的(8-10年)的临床和血管造影随访的数据资料。

Circ Res:Dynamin相关蛋白1抑制可以减轻氧化应激下心血管的钙化

细胞的分化和心血管疾病过程中伴随着线粒体的变化。动力蛋白相关蛋白1(DRP1)是线粒体分裂的关键调节剂。近期,一项发表在杂志Circ Res上的研究评估了DRP1在心血管钙化中的作用。探讨了成骨促进条件对DRP1的影响,以及DRP1抑制剂是否改变心血管钙化的发展。此项研究采用免疫组织化学检测,发现DRP1富集于人颈动脉钙化区。原代血管平滑肌细胞(SMC)的成骨分化增加了DRP1表达。人SMC在成骨

ADA 2017:DEVOTE研究证实德谷胰岛素具有心血管安全性且严重低血糖大幅减少

6月12日,心血管安全性终点研究DEVOTE在ADA2017重磅公布,该研究首次头对头比较了两种基础胰岛素——德谷胰岛素和甘精胰岛素U100在2型糖尿病患者中的心血管安全性。结果证实,新型超长效胰岛素制剂德谷胰岛素的心血管安全性与甘精胰岛素U100相当,但较甘精胰岛素U100显着降低了40%的严重低血糖,夜间严重低血糖显着降低53%。